SMS Lifesciences India Limited (SMSLIFE.BO)
INR 1350.85
(2.06%)
INR 1350.85
(2.06%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.05 Billion INR | -2.11% |
| 2022 | 3.12 Billion INR | -10.01% |
| 2021 | 3.47 Billion INR | 34.9% |
| 2020 | 2.57 Billion INR | 0.32% |
| 2019 | 2.56 Billion INR | -31.24% |
| 2018 | 3.73 Billion INR | 78.7% |
| 2017 | 2.08 Billion INR | -1.63% |
| 2016 | 2.12 Billion INR | 0.0% |
| 2015 | - INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 925.48 Million INR | 2.84% |
| 2023 Q3 | 720.53 Million INR | 4.03% |
| 2023 FY | 3.05 Billion INR | -2.11% |
| 2023 Q2 | 692.61 Million INR | -7.22% |
| 2023 Q1 | 746.51 Million INR | 22.95% |
| 2023 Q4 | 899.91 Million INR | 24.9% |
| 2022 Q2 | 812.59 Million INR | -1.23% |
| 2022 Q3 | 882.93 Million INR | 8.66% |
| 2022 Q4 | 607.19 Million INR | -31.23% |
| 2022 Q1 | 822.75 Million INR | -11.74% |
| 2022 FY | 3.12 Billion INR | -10.01% |
| 2021 Q4 | 932.21 Million INR | 2.37% |
| 2021 FY | 3.47 Billion INR | 34.9% |
| 2021 Q2 | 867.51 Million INR | 13.74% |
| 2021 Q1 | 762.7 Million INR | 2.54% |
| 2021 Q3 | 910.59 Million INR | 4.97% |
| 2020 Q2 | 617.59 Million INR | 12.81% |
| 2020 FY | 2.57 Billion INR | 0.32% |
| 2020 Q1 | 547.49 Million INR | 30.88% |
| 2020 Q3 | 665.69 Million INR | 7.79% |
| 2020 Q4 | 743.79 Million INR | 11.73% |
| 2019 Q2 | 763.66 Million INR | -16.85% |
| 2019 FY | 2.56 Billion INR | -31.24% |
| 2019 Q4 | 418.3 Million INR | -10.22% |
| 2019 Q3 | 465.92 Million INR | -38.99% |
| 2019 Q1 | 918.41 Million INR | -28.05% |
| 2018 Q1 | 598.78 Million INR | 10.62% |
| 2018 FY | 3.73 Billion INR | 78.7% |
| 2018 Q4 | 1.27 Billion INR | 23.83% |
| 2018 Q3 | 1.03 Billion INR | 15.55% |
| 2018 Q2 | 892.02 Million INR | 48.97% |
| 2017 Q3 | 664.77 Million INR | 30.24% |
| 2017 Q4 | 541.28 Million INR | -18.58% |
| 2017 FY | 2.08 Billion INR | -1.63% |
| 2017 Q1 | 413.36 Million INR | -26.19% |
| 2017 Q2 | 510.43 Million INR | 23.48% |
| 2016 Q1 | 583.37 Million INR | 0.0% |
| 2016 Q3 | 610.94 Million INR | 24.42% |
| 2016 Q2 | 491.02 Million INR | -15.83% |
| 2016 FY | 2.12 Billion INR | 0.0% |
| 2016 Q4 | 560.02 Million INR | -8.33% |
| 2015 FY | - INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 31.27 Million INR | -9683.468% |
| Biocon Limited | 147.55 Billion INR | 97.927% |
| Blue Jet Healthcare Limited | 7.11 Billion INR | 57.004% |
| Concord Biotech Limited | 10.16 Billion INR | 69.914% |
| Dishman Carbogen Amcis Limited | 26.15 Billion INR | 88.303% |
| FERMENTA BIOTECH LIMITED | 3.35 Billion INR | 8.849% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.65 Million INR | -185245.086% |
| Lyka Labs Limited | 1.05 Billion INR | -191.022% |
| Panacea Biotec Limited | 5.51 Billion INR | 44.566% |
| SAMSRITA LABS LIMITED | - INR | -Infinity% |
| Servoteach Industries Limited | - INR | -Infinity% |
| Supriya Lifescience Limited | 5.7 Billion INR | 46.358% |
| Syngene International Limited | 34.88 Billion INR | 91.23% |
| TAKE Solutions Limited | 656.08 Million INR | -366.343% |
| Titan Biotech Limited | 1.64 Billion INR | -86.478% |
| Transgene Biotek Limited | 2.34 Million INR | -130150.49% |
| Vanta Bioscience Limited | 97.22 Million INR | -3046.781% |